MARLBOROUGH, Mass.,
Aug. 31, 2017 /PRNewswire/ --
Hologic, Inc. (Nasdaq: HOLX) today announced U.S. commercial
availability of the Brevera® breast biopsy system with
CorLumina® imaging technology, a groundbreaking
real-time breast biopsy and verification system that enhances
workflow, improves the patient experience and streamlines the
entire biopsy process from start to finish. The first-of-its-kind
Brevera system is designed to increase biopsy accuracy with
real-time imaging that delivers valuable information at the point
of care, enabling clinicians to make informed decisions with
confidence.
The Brevera system is the world's first and only breast biopsy
solution to combine tissue acquisition, real-time imaging, sample
verification and advanced post-biopsy handling in one, integrated
system. Designed for 2D and 3D™ breast biopsy, the
innovative system allows physicians to perform fast and efficient
procedures that save costs and improve the patient
experience.1 The new product represents another
major advance in Hologic's ongoing efforts to improve patient
satisfaction and workflow in the biopsy suite.
Until now, radiologists performing stereotactic breast biopsy
procedures to diagnose breast cancer were often required to leave
the patient under compression while they moved to another room to
image and verify tissue samples. This leads to lengthy procedure
times and anxious, uncomfortable patients, and can interrupt
facility screening schedules. With the Brevera system, radiologists
are able to obtain and image tissue samples in the procedure room
in just a few seconds, potentially saving up to 10 minutes per
patient and cutting the procedure time by up to 25
percent.2
"We're proud to launch the Brevera system, a major breakthrough
for radiologists who, for the first time, will be able to image and
verify tissue samples in real-time in the procedure room," said
Pete Valenti, Hologic's Division
President, Breast and Skeletal Health Solutions. "The Brevera
system provides clinicians with more information at the point of
care and women with a vastly improved experience, resulting in
significant cost and time savings without compromising accuracy or
patient health outcomes. The system transforms the stereotactic
breast biopsy procedure as we know it, and serves as further proof
of Hologic's commitment to better serve the needs of our customers
and their patients."
In addition to saving facility resources and physician time
during a breast biopsy procedure, the Brevera system's proprietary
CorLumina imaging technology helps enhance workflow across multiple
departments within a health system. The CorLumina imaging system
automates the tissue sample collection and separation process,
which allows patient tissue to be sent to pathology with little or
no manual handling and protects the integrity of samples. The
system also features PACS integration for advanced image sharing
and transfer of patient records.
The Brevera system is designed for use with Hologic's Affirm®
prone biopsy system, Affirm® breast biopsy guidance system, and
MultiCare® Platinum system, as well as most upright
and prone systems on the market. For more information please visit:
www.BreveraBiopsy.com
About Hologic, Inc.
Hologic, Inc. is an innovative medical technology company
primarily focused on improving women's health and well-being
through early detection and treatment. For more information on
Hologic, visit www.hologic.com.
Hologic, 3D, Affirm, Brevera, CorLumina, MultiCare, The Science
of Sure, and associated logos are trademarks and/or registered
trademarks of Hologic, Inc. and/or its subsidiaries in the United States and/or other countries.
Forward-Looking Statements
This news release may contain forward-looking information that
involves risks and uncertainties, including statements about the
use of Hologic products. There can be no assurance these products
will achieve the benefits described herein or that such benefits
will be replicated in any particular manner with respect to an
individual patient, as the actual effect of the use of the products
can only be determined on a case-by-case basis. In addition, there
can be no assurance that these products will be commercially
successful or achieve any expected level of sales. Hologic
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any such statements presented
herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or
statements are based.
This information is not intended as a product solicitation or
promotion where such activities are prohibited. For specific
information on what products are available for sale in a particular
country, please contact a local Hologic sales representative or
write to womenshealth@hologic.com.
Media Contact:
Jane
Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
Investor Contact:
Michael Watts
858.410.8588
michael.watts@hologic.com
1 3D biopsy only when used with the Affirm breast
biopsy system.
2 2015 Kadence International survey of 200 healthcare
professionals.
View original content with
multimedia:http://www.prnewswire.com/news-releases/hologic-announces-availability-of-new-brevera-breast-biopsy-system-with-corlumina-imaging-technology-300511832.html
SOURCE Hologic, Inc.